Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 4/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | YAP1 | P46937 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28898382 | 0.85 | NPC1 (0.62) | NPC1GPR119PKM | |
| SCHEMBL210422 | 0.83 | EPHX2 (0.71) | EPHX2POLBMAPTNPC1GRIN2B | |
| SCHEMBL210449 | 0.82 | KCNA5 (0.59) | — | |
| SCHEMBL3449537 | 0.81 | ALDH1A1 (0.54) | MAPTNPC1GPR119GRIN2BHTT | |
| SCHEMBL13930889 | 0.79 | GPR119 (0.56) | GLSGPR119GRIN2BFAAHHTT | |
| SCHEMBL4773996 | 0.78 | GPR119 (0.51) | GLSGPR119FAAHKDM4EPKM | |
| SCHEMBL998770 | 0.77 | GPR119 (0.55) | POLBMAPTNPC1GPR119 | |
| SCHEMBL12824492 | 0.77 | EPHX2 (1.00) | EPHX2POLBMAPTNPC1HTT | |
| SCHEMBL15043773 | 0.77 | GLS (1.00) | GLS | |
| SCHEMBL13326821 | 0.76 | CNR1 (0.49) | MAPTNPC1GPR119HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963315-B1 | ENZYME INHIBITORS | CANCER REC TECH LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| EP-1963315-A2 | ENZYME INHIBITORS | The Institute of Cancer Research (GB) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007072017-A2 | ENZYME INHIBITORS | THE INSTITUTE OF CANCER RESEARCH (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | GLS 1899/4885EPHX2 1006/4885POLB 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.